Tofacitinib Citrate

**Semantic type:** Pharmacologic Substance

**Definition:** The citrate salt form of tofacitinib, an orally bioavailable inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon oral administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha (IFN-a) and -beta (IFN-b), and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.

**Synonyms:** - 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo(2,3-d)Pyrimidin-4-ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1) - CP-690,550-10 - TOFACITINIB CITRATE - Tasocitinib Citrate - Xeljanz - Xeljanz